Indication: For use in the treatment of duodenal ulcers, as a diuretic, and in the treatment of glaucoma, and may also be useful in the treatment of seizures associated with epilepsy.
Pharmacology: Ethoxzolamide, a sulfonamide, inhibits carbonic anhydrase activity in proximal renal tubules to decrease reabsorption of water, sodium, potassium, bicarbonate. It also decreases carbonic anhydrase in the CNS, increasing the seizure threshold. This reduction in carbonic anhydrase also reduces the intraocular pressure in the eye by decreasing aqueous humor.
Mechanism Of Action: Ethoxzolamide binds and inhibits carbonic anhydrase I. Carbonic anhydrase plays an essential role in facilitating the transport of carbon dioxide and protons in the intracellular space, across biological membranes and in the layers of the extracellular space. The inhibition of this enzyme effects the balance of applicable membrane equilibrium systems.
Drug Category: Diuretics; Carbonic Anhydrase Inhibitors
Absorption: Rapidly absorbed with 65% bioavailability
Interactions:
DrugBank: Interactions for Ethoxzolamide
Interactions for Ethoxzolamide:
Ethoxzolamide may increase the action of tricyclics, amphetamines,
procainamide, and quinidine. It may increase excretion of barbiturates, lithium, and ASA and may also increase the
toxicity of salicylates. Coadministration of ethoxzolamide with other diuretics, amphotericin B, and corticosteroids
may cause hypokalemia.
Chemical IUPAC Name: 6-ethoxybenzothiazole-2-sulfonamide
